^
    Back
    Association details:
    Biomarker:TP53 expression
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP

    Published date:
    11/06/2019
    Excerpt:
    We analyzed 347 newly diagnosed de novo DLBCL cases uniformly treated with R-CHOP in British Columbia....Both p53mut and TP53+ were associated with poor overall survival (OS) (p=0.004 and p=0.007, respectively) and disease-specific survival (DSS) (p=0.003 and p=0.001, respectively). 
    DOI:
    https://doi.org/10.1182/blood-2019-121943